News Releases

London, UK, 26th September 2006
Pharmaprojects highlights the current dearth of pharmaceuticals in development for protozoal diseases

On the opening of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, Pharmaprojects, the world’s leading source of business-critical intelligence on drugs in global R&D, today highlights the notable lack of drugs in development to treat non-malarial protozoal infections.

The latest information shows that of 125 products known to have been in development for non-malarial protozoal infections since 1980, only 14 are currently in active development. A further 9 have been launched, while 102 are reported to have ceased development. Of the 102 ceased products, 38 have been positively confirmed as discontinued.

Of those drugs in the current pipeline, aminosidine (developed by the Institute for OneWorld Health) was submitted for registration in India for the prevention of leishmaniasis and was approved only a few weeks ago. 

The other compounds, mostly focus on trypanosomiasis (6 products), while 4 tackle leishmaniasis. There are also 2 products, one in preclinical trials and one in Phase II clinical trials, that only suggest a possible use as an antiprotozoal, their main focus being on anticancer uses.

Of the launched products, 3 are for leishmaniasis, 2 for trypanosomiasis [1 for the American (also known as Chagas disease) variant, and the other for the African (sleeping sickness) variant], and 2 for trichomoniasis and amoebiasis. Click to read more...

September 2006
Uncertainty surrounds the antidiabetic glitazars

21 August 2006
Pharmaprojects breaks down the anticancer target family landscape

19 May 2005
Entecavir could dominate first-line hepatitis-B monotherapy, reports Pharmaprojects

31 March 2005
New Japanese company, Astellas, set to be strong in neurology and cardiovascular disease reports Pharmaprojects

16 March 2005
Tysabri withdrawal prompts questions about multiple sclerosis drug target, notes Pharmaprojects

01 February 2005
Pharmaprojects reports low number of drugs in development for post-tsunami diseases

01 October 2004
Pfizer likely to benefit from Vioxx withdrawal, notes Pharmaprojects

27 September 2004
Pharmaprojects highlights changing trends in the R&D focus of drugs targeting breast cancer

13 August 2004
Pharmaprojects launches new searchable drug target and Lipinski fields

12 July 2004
Antiretroviral Development Strategies on the Increase 

5 April 2004 - Pharmaprojects on the Web goes weekly!

As of 10 April 2004, Pharmaprojects on the Web subscribers will receive weekly data updates as part of their annual subscription. This process will be automatic and will not require any software upgrades. Last year, Pharmaprojects on the Web was developed using the latest Microsoft^® .NET Framework and is today the most powerful, versatile and fully-searchable web-based database of its kind available. The addition of weekly updates will enable users to access our quality-driven editorial more quickly and bring you the most up-to-date information available. To find our more about weekly updates, please contact your regional Account Manager.

24 March 2004
Pharmaprojects reports a startlingly low number of new anti-TB drugs under development on World TB Day

02 February 2004
Pharmaprojects analysis reveals good pipeline fit between merger candidates Sanofi-Synthelabo and Aventis

01 December 2003
Pharmaprojects highlights urgent need to intensify AIDS drug and vaccine development

07 October 2003
Pharmaprojects reveals that biotechnology appears to be the key to the future of cancer therapy

30 July 2003
Obesity - treating an addiction

21 July 2003
Pharmaprojects reports on the explosive growth of the controlled-release market

13 June 2003
Pharmaprojects highlights a rise in R&D and an emerging drug delivery strategy which may help to combat the diabetes epidemic

13 June 2003
Pharmaprojects highlights a rise in R&D and an emerging drug delivery strategy

12 May 2003
Pharmaprojects launches searchable pharmacokinetics fields

30 January 2003
Scrip Reports announces a major new report: Proteomics Made Simple

18 November 2002
Antiangiogenics - a hot topic in cancer research

15 August 2002
Pharmaprojects highlights unmet need for analgesics to treat neuropathic pain

10 June 2002
Biotech marches on despite low success rates and faltering investment 

22 May 2002
Rise in the number of drugs in active R&D could lead to a future bumper harvest for the pharma industry

24 April 2002
Pharmaprojects keeps pace with drug delivery explosion

20 March 2002
Analysts predict product crowding in tomorrow's cancer market

For more information, please contact:

Editorial information	Product information
Ian Lloyd, Managing Editor	Nicholas Johnston, Marketing Supervisor
Tel: +44 (0)20 7017 6886	Tel: +44 (0)20 7017 6861
Fax: +44 (0)20 7017 6878	Fax: +44 (0)20 7017 6905
About PJB Publications PJB Publications is a trading division of T&F Informa. Specialist areas of knowledge include pharmaceuticals on which it publishes the twice-weekly newsletter Scrip, medical devices and diagnostics, biotechnology, veterinary, crop protection, agribusiness, clinical research and regulatory affairs.

Back to top